ClinicalTrials.gg
RecruitingNCT06963281Updated Sep 25, 2026

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

A Phase 1 interventional study of IBI3020 in Solid Tumors, sponsored by Fortvita Biologics (USA)Inc.. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Fortvita Biologics (USA)Inc. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Sep 25, 2026Sponsor changedStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
285
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Fortvita Biologics (USA)Inc. is the lead sponsor of 5 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must satisfy all of the following criteria to be enrolled into the study:

  1. Participants have the ability to understand and give written for participation in this trial, including all evaluations and procedures as specified by this protocol;
  2. Male or female participants ≥ 18 years old. For Part 1, age ≥ 18 years and ≤ 75 years;
  3. or cytologically confirmed unresectable, locally advanced or solid tumors which have received available standard therapies and have disease progression, or unacceptable toxic effects, or ;
  4. At least 1 as defined per v1.1 within 28 days prior to the first dose of IBI3020;
  5. (ECOG) Performance Status score of 0-1;
  6. Minimum of 12 weeks;
  7. Adequate bone marrow and organ function confirmed at screening period;
  8. Participants, both male and female, who are not of or who agree to use at least 1 highly effective method of during the study.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Previous treatment with CEACAM5-targeted therapy;
  2. Prior anti-cancer therapy within the ;
  3. Received within 4 weeks or cancer vaccine within 3 months;
  4. Potent cytochrome P450 3A4 () inhibitors within 2 weeks or 5 half-lives;
  5. Has adverse reactions resulting from previous anti-tumor therapies, which have not resolved to Grade 0 or 1 toxicity according to v5.0;
  6. Known allergies, , or intolerance to IBI3020 or its ;
  7. Undergone major surgery within 4 weeks, or who have severe unhealed wounds;
  8. Known symptomatic central nervous system (CNS) ;
  9. Uncontrolled diseases or conditions;
  10. History of pneumonitis requiring therapy, or history of lung diseases;
  11. History of thromboembolic event within 6 months;
  12. Under neurological, psychiatric or social condition;
  13. Women who are pregnant, have positive results in pregnancy test or are lactating;
  14. Not eligible to participate in this study at the discretion of the investigator;
  15. Participating in any other interventional clinical research.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    IBI3020

    Drug: IBI3020

Interventions

  • DrugIBI3020

    Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection

06

What researchers measure

Primary outcomes

  1. Numbers of subjects with adverse events

    defined as any untoward medical occurrence, whether or not there is a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed

    Time frame: Up to 3 years

  2. Number of subjects with clinically significant changes in physical examination results

    Clinically significant abnormal physical examination findings reported by the investigator.

    Time frame: Up to 3 years

  3. Number of subjects with clinically significant changes in electrocardiogram

    Clinically significant abnormal electrocardiogram findings reported by the investigator.

    Time frame: Up to 3 years

  4. Number of subjects with clinically significant changes in vital signs

    Vital signs including body temperature, pulse, respiratory rate, oxygen saturation by pulse oximetry at rest and blood pressure

    Time frame: Up to 3 years

  5. Dose limiting toxicities (DLTs)

    Dose limiting toxicities (DLTs) to establish MTD and/or RP2D.

    Time frame: Up to 21 days

  6. objective response rate (ORR)

    objective response rate (ORR) as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  7. Number of subjects with clinically significant changes in laboratory parameters

    Clinically significant abnormal laboratory parameters findings reported by the investigator.

    Time frame: Up to 3 years

Secondary outcomes

  1. area under the curve (AUC)

    area under the curve (AUC) of single and multiple doses of IBI3020

    Time frame: Up to 3 years

  2. maximum concentration (Cmax)

    maximum concentration (Cmax) of single and multiple doses of IBI3020

    Time frame: Up to 3 years

  3. time to maximum concentration (Tmax)

    time to maximum concentration (Tmax) of single and multiple doses of IBI3020

    Time frame: Up to 3 years

  4. clearance (CL)

    clearance (CL) of single and multiple doses of IBI3020

    Time frame: Up to 3 years

  5. apparent volume of distribution (V)

    apparent volume of distribution (V) of single and multiple doses of IBI3020

    Time frame: Up to 3 years

  6. half-life (t1/2)

    half-life (t1/2) of IBI3020 to the last administration of IBI3020

    Time frame: Up to 3 years

  7. anti-drug antibody (ADA)

    Incidence and characterization of anti-drug antibody (ADA).

    Time frame: Up to 3 years

  8. objective response rate (ORR)

    objective response rate (ORR) as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  9. duration of response (DoR)

    duration of response (DoR) as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  10. time to response (TTR)

    time to response (TTR) as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  11. progression free survival (PFS)

    as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  12. disease control rate (DCR)

    disease control rate (DCR)as evaluated per the RECIST v1.1 criteria.

    Time frame: Up to 3 years

  13. overall survival (OS)

    OS is defined as the time from the date of first dose of study drug until the date of death from any cause.

    Time frame: From date of randomization until the date of first documented date of death from any cause, assessed up to 36 months

07

Study locations

9 of 9 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 8, 2025
StartActual
Apr 29, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 United States)
  • Mayo Clinic - Arizona · Phoenix, United States
  • Montefiore Cancer Center · New York, United States
Show 2 removed
  • Mayo Clinic - Arizona · Pheonix, United States
  • Montefiore Cancer Center · New york, United States
Sep 25, 2026
Contact
Study contact changed: s•••@innoventbio.com · •••6088→c•••@fortvitabio.com · •••0985. See the current contact
Sep 25, 2026
Site contacts
Changed at 7 sites. See the sites
Show 7 sites
  • Mayo Clinic - Florida · Jacksonville, United StatesContact L•••@mayo.edu · •••2000→c•••@fortvitabio.com · •••0985
  • Mayo Clinic - Rochester · Rochester, United StatesContact X•••@mayo.edu · •••1667→c•••@fortvitabio.com · •••0985
  • NEXT Houston · Houston, United StatesContact j•••@nextoncology.com · •••7900→c•••@fortvitabio.com · •••0985
  • NEXT Dallas · Irving, United StatesContact s•••@nextoncology.com · •••8800→c•••@fortvitabio.com · •••0985
  • The sixth affiliated hospital, Sun Yat-sen University · Guangzhou, ChinaContact 1•••@163.com · •••4000→c•••@fortvitabio.com · •••0985
  • Shandong Cancer Hospital · Jinan, ChinaContact s•••@126.com · •••4777→c•••@fortvitabio.com · •••0985Contact removed 1•••@163.com · •••4777
  • Shanxi Cancer Hospital · Taiyuan, ChinaContact z•••@163.com · •••1611→c•••@fortvitabio.com · •••0985
Sep 25, 2026
Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.→Fortvita Biologics (USA)Inc.; Collaborators added: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.; collaborators removed: Fortvita Biologics (USA)Inc.
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 United States)
    • Mayo Clinic - Arizona · Phoenix, United States
    • Montefiore Cancer Center · New York, United States
    Show 2 removed
    • Mayo Clinic - Arizona · Pheonix, United States
    • Montefiore Cancer Center · New york, United States
    Sponsor Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.→Fortvita Biologics (USA)Inc.; Collaborators added: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.; collaborators removed: Fortvita Biologics (USA)Inc.
    Contact Study contact changed: s•••@innoventbio.com · •••6088→c•••@fortvitabio.com · •••0985. See the current contact
    Site contacts Changed at 7 sites. See the sites
    Show 7 sites
    • Mayo Clinic - Florida · Jacksonville, United StatesContact L•••@mayo.edu · •••2000→c•••@fortvitabio.com · •••0985
    • Mayo Clinic - Rochester · Rochester, United StatesContact X•••@mayo.edu · •••1667→c•••@fortvitabio.com · •••0985
    • NEXT Houston · Houston, United StatesContact j•••@nextoncology.com · •••7900→c•••@fortvitabio.com · •••0985
    • NEXT Dallas · Irving, United StatesContact s•••@nextoncology.com · •••8800→c•••@fortvitabio.com · •••0985
    • The sixth affiliated hospital, Sun Yat-sen University · Guangzhou, ChinaContact 1•••@163.com · •••4000→c•••@fortvitabio.com · •••0985
    • Shandong Cancer Hospital · Jinan, ChinaContact s•••@126.com · •••4777→c•••@fortvitabio.com · •••0985Contact removed 1•••@163.com · •••4777
    • Shanxi Cancer Hospital · Taiyuan, ChinaContact z•••@163.com · •••1611→c•••@fortvitabio.com · •••0985
    + 4 other changes: index terms, identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06963281
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Apr 29, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Fortvita Biologics CT.gov Call Center
Contact
ct.govNotifications@fortvitabio.com
650-370-0985

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion